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A B S T R A C T
Background
Prevention of relapse is a major issue in the management of quiescent Crohn’s disease (CD). Current therapies (e.g. methotrexate,
biologics, 6-mercaptopurine and azathioprine) may be effective for maintaining remission in CD, but these drugs may cause significant
adverse events. Interventions that are effective and safe for maintenance of remission in CD are desirable.
Objectives
The primary objectives were to evaluate the efficacy and safety of enteral nutrition for the maintenance of remission in CD and to
assess the impact of formula composition on effectiveness.
Search methods
We searched MEDLINE, Embase, CENTRAL, the Cochrane IBD Group Specialized Register and clinicaltrials.gov from inception to
27 July 2018. We also searched references of retrieved studies and reviews.
Selection criteria
Randomised controlled trials (RCTs) including participants of any age with quiescent CD were considered for inclusion. Studies that
compared enteral nutrition with no intervention, placebo or any other intervention were selected for review.
Data collection and analysis
Two authors independently screened studies for inclusion, extracted data and assessed methodological quality using the Cochrane risk
of bias tool. The primary outcome was clinical or endoscopic relapse as defined by the primary studies. Secondary outcomes included
anthropometric measures (i.e. height and weight), quality of life (QoL), adverse events, serious adverse events and withdrawal due to
adverse events. We calculated the risk ratio and 95% confidence interval (CI) for dichotomous outcomes. For continuous outcomes,
we calculated the mean difference and 95% CI. A random-effects model was used for the statistical analysis. We used the GRADE
criteria to assess the overall certainty of the evidence supporting the primary outcome and selected secondary outcomes.
Main results
Four RCTs (262 adult participants) met the inclusion criteria. One study (N = 33) compared an elemental diet to a non-elemental
(polymeric) diet.One study (N =51) compared a half elemental diet to a regular free diet. Another study (N = 95) compared an elemental
diet to 6-mercaptopurine (6-MP) or a no treatment control group. One study (N= 83) compared a polymeric diet to mesalamine. Two
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studies were rated as high risk of bias due to lack of blinding or incomplete outcome data. The other two studies were judged to have
an unclear risk of bias. The studies were not pooled due to differences in control interventions and the way outcomes were assessed.
The effect of an elemental diet compared to a polymeric diet on remission rates or withdrawal due to adverse events is uncertain. Fifty-
eight per cent (11/19) of participants in the elemental diet group relapsed at 12 months compared to 57% (8/14) of participants in the
polymeric diet group (RR 1.01, 95% CI 0.56 to 1.84; very low certainty evidence). Thirty-two per cent (6/19) of participants in the
elemental diet group were intolerant to the enteral nutritional formula because of taste or smell and were withdrawn from the study in
the first 2 weeks compared to zero participants (0/14) in the polymeric diet group (RR 9.75, 95% CI 0.59 to 159.93; low certainty
evidence). Anthropometric measures, QoL, adverse events and serious adverse events were not reported as outcomes.
The effect of an elemental diet (half of total daily calorie requirements) compared to a normal free diet on relapse rates is uncertain.
Thirty-five per cent (9/26) of participants in the elemental diet group relapsed at 12 months compared to 64% (16/25) of participants
in the free diet group (RR 0.54, 95% CI 0.30 to 0.99; very low certainty evidence). No adverse events were reported. This study
reported no differences in weight change between the two diet groups. Height and QoL were not reported as outcomes.
The effect of an elemental diet compared to 6-MP on relapse rates or adverse events is uncertain. Thirty-eight per cent (12/32) of
participants in the elemental diet group relapsed at 12 months compared to 23% (7/30) of participants in the 6-MP group (RR 1.61;
95% CI 0.73 to 3.53; very low certainty evidence). Three per cent (1/32) of participants in the elemental diet group had an adverse
event compared to 13% (4/30) of participants in the 6-MP group (RR 0.23, 95% CI 0.03 to 1.98; low certainty evidence). Adverse
events in the elemental diet group included surgery due to worsening CD. Adverse events in the 6-MP group included liver injury (n =
2), hair loss (n = 1) and surgery due to an abscess (n = 1). No serious adverse events or withdrawals due to adverse events were reported.
Weight, height and QoL were not reported as outcomes
The effect of a polymeric diet compared to mesalamine on relapse rates and weight is uncertain. Forty-two per cent (18/43) of
participants in the polymeric diet group relapsed at 6 months compared to 55% (22/40) of participants in the mesalamine group (RR
0.76; 95% CI 0.49 to 1.19; low certainty evidence). The mean difference in weight gain over the study period was 1.9 kg higher in
the polymeric diet group compared to mesalamine (95% CI -4.62 to 8.42; low certainty evidence). Two participants in the polymeric
diet group experienced nausea and four had diarrhoea. It is unclear if any participants in the mesalamine group had an adverse event.
Height, QoL, serious adverse events and withdrawal due to adverse events were not reported as outcomes.
Authors’ conclusions
The results for the outcomes assessed in this review are uncertain and no firm conclusions regarding the efficacy and safety of enteral
nutrition in quiescent CD can be drawn. More research is needed to determine the efficacy and safety of using enteral nutrition as
maintenance therapy in CD. Currently, there are four ongoing studies (estimated enrolment of 280 participants). This review will be
updated when the results of these studies are available.
P L A I N L A N G U A G E S U M M A R Y
Enteral nutrition (liquid feeds) for maintenance of remission in Crohn’s disease
What is Crohn’s disease?
Crohn’s disease is a chronic inflammatory disease of the intestines that frequently occurs in the lower part of the small intestine (ileum).
Symptoms include abdominal pain, diarrhoea and weight loss. When people with Crohn’s disease are experiencing symptoms the
disease is considered ’active’. When the symptoms stop, it is called ’remission’. When people in remission experience symptoms it is
called a ’relapse’.
What is enteral nutrition?
Enteral nutrition is a feedingmethodwhere a person’s daily caloric intake is delivered via a liquid diet using theGI tract. Enteral nutrition
can be administered by mouth or by tube feeding, where a tube is inserted through the nose or abdomen into the stomach to deliver the
liquid feed. Enteral nutrition is a form of nutritional therapy for Crohn’s disease patients. The mechanism by which enteral nutrition
may influence inflammation is unknown and is being studied. Enteral nutrition can be classified as elemental and non-elemental (semi-
elemental and polymeric) diets. Elemental diets are composed of amino-acids (organic compounds), fats, sugars, vitamins and minerals.
Elemental diets are easily absorbed and digested. Non-elemental diets are based on oligopeptide (organic compounds composed of 2
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to 20 amino-acids) or whole protein sources. Non-elemental diets are best for people who can digest and absorb nutrients without
difficulty.
What is 6-mercaptopurine?
6-Mercaptopurine is an immunosuppressive drug that is thought to reduce inflammation in people with Crohn’s disease by blocking
the immune system.
What is mesalamine?
Mesalamine is a 5-aminosalicylic acid drug. 5-Aminosalicylic drugs are thought to treat Crohn’s disease by reducing inflammation in
the gastrointestinal tract. These drugs are usually taken by mouth.
What did the researchers investigate?
The researchers studied whether enteral nutrition helps to maintain remission in people with Crohn’s disease. The researchers also
investigated whether one type of enteral nutrition was better than another (e.g. elemental vs.non-elemental) for maintaining remission
in people with Crohn’s disease.
What did the researchers find?
Four studies including 262 adult participants with Crohn’s disease in remission were included. One study (33 participants) compared
an elemental diet to a non-elemental (polymeric) diet. One study (51 participants) compared an elemental diet to a normal diet (no
supplements). One study (95 participants) compared an elemental diet to 6-mercaptopurine or a no treatment control group. One study
(83 participants) compared a non-elemental polymeric diet to mesalamine. The researchers searched the medical literature extensively
up to 27 July 2018.
The study comparing an elemental diet to a polymeric diet found no difference in remission rates at 12 months. Six elemental diet
participants were not able to tolerate the enteral nutritional formula because of taste or smell and were withdrawn from the study.
Participants who received half of their total daily calorie requirements as elemental diet and the remaining half by normal diet had a
lower chance of relapse at 12 months compared to participants who received a free diet. No side effects were reported in this study.
The study comparing an elemental diet to 6-mercaptopurine did not show any difference in relapse rates at 12 months. There was no
difference in side effect rates. The only side effect reported in the elemental diet group was surgery due to worsening Crohn’s disease.
Side effects in the 6-mercaptopurine group included liver injury in two participants, hair loss in one participant and surgery to treat an
abscess in one participant. The study comparing a polymeric diet to mesalamine found no difference in relapse rates at six months. Two
participants the polymeric diet group experienced nausea and four had diarrhoea. It is unclear if any participants in the mesalamine
group had side effects. No serious side effects were reported in any of the studies.
The results for the outcomes assessed in this review are uncertain and no firm conclusions regarding the effectiveness and safety of
enteral nutrition for maintenance of remission in Crohn’s disease can be drawn. More research is needed to determine the effectiveness
and safety of using enteral nutrition as maintenance therapy in Crohn’s disease. Currently, there are four ongoing studies (estimated
enrolment of 280 participants). This review will be updated when the results of these studies are available.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Elemental diet compared to non-elemental (polymeric) diet for maintenance of remission in Crohn’s disease
Patient or population: Part icipants with Crohn’s disease in remission
Setting: Outpat ient
Intervention: Elemental formula supplements
Comparison: Polymeric formula supplements
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk polymeric formula
supplements
Risk with Elemental
formula supplements
Relapse
Follow-up: 12 months
571 per 1,000 577 per 1,000
(320 to 1,051)
RR 1.01
(0.56 to 1.84)
33
(1 RCT)
⊕©©©
VERY LOW 12
Change in weight Not reported This outcome was not
reported
Change in height Not reported This outcome was not
reported
Change in quality of life Not reported This outcome was not
reported
Adverse events Not reported This outcome was not
reported
Serious adverse events Not reported This outcome was not
reported
Withdrawals due to ad-
verse events
Follow-up: 12 months
0 per 1,000 0 per 1,000
(0 to 0)
RR 9.75
(0.59 to 159.93)
33
(1 RCT)
⊕⊕©©
LOW 3
Six part icipants with-
drew f rom the elemen-
tal diet group for intol-
erance to the elemental
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f ormula due to taste or
smell
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to unclear risk of bias for random sequence generat ion, allocat ion concealment, blinding of
part icipants and personnel and blinding of outcome assessment
2 Downgraded two levels due to very serious imprecision (19 events)
3 Downgraded two levels due to very serious imprecision (6 events)
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B A C K G R O U N D
Crohn’s disease is a chronic relapsing condition with a high mor-
bidity. There is no cure for Crohn’s disease. Treatment is aimed at
inducing and maintaining remission of disease activity, correcting
malnutrition, addressing complications, and thereby improving
the quality of life of patients. In children, a major additional goal
is to facilitate normal growth and pubertal development which are
frequently impeded. Whilst enteral nutrition may be effective for
induction of remission in active Crohn’s disease (Akobeng 2000;
Gonzalez-Huix 1993; Heuschkel 2000; Narula 2018; Thomas
1993), rapid return of gastrointestinal symptoms after resumption
of normal diet is common (Jones 1985; Wilschanski 1996), and
many patients end up receiving corticosteroids (Murphy 2001).
Prevention of relapses is a major issue in the management of
Crohn’s disease especially as being in remission is associated with
improved quality of life (Lichtenstein 2004). Whilst a num-
ber of treatment regimens are effective for induction of clini-
cal remission in active Crohn’s disease, no treatment is available
that can completely prevent relapse of the disorder (Biancone
2003). Corticosteroids (Steinhart 2003), and 5-ASA prepara-
tions (Akobeng 2016), are not effective for the maintenance of
remission. Methotrexate (Feagan 2000; Patel 2014), infliximab
(Hanauer 2002), adalimumab (Colombel 2007), vedolizumab
(Sandborn 2013), and the antimetabolite, 6-mercaptopurine and
its prodrug, azathioprine are effective for maintenance of remis-
sion (Chande 2015; Feagan 2003), but these drugs may cause sig-
nificant adverse events.
In the last three decades, studies have been completed that suggest
that long-term enteral nutritional supplementation, in addition to
unrestricted normal food may prolong the period of remission and
reduce relapse rates in patients with Crohn’s disease (Koga 1993;
Verma 2000). Enteral nutrition can be classified as elemental and
non-elemental (semi-elemental and polymeric) diets. Elemental
diets are composed of amino-acids (organic compounds), fats, sug-
ars, vitamins and minerals. Elemental diets are easily absorbed and
digested. Non-elemental diets are based on oligopeptide (organic
compounds composed of 2 to 20 amino-acids) or whole protein
sources. Non-elemental diets are best for people who can digest
and absorb nutrients without difficulty. The exact mechanism by
which enteral nutrition may modulate the inflammatory process
in Crohn’s disease is unknown. Several mechanisms have been pro-
posed (Lewis 1994). These include provision of essential nutri-
ents, reduction of antigenic load, alteration of bowel flora, and
improved immune function. Differences in the composition of
long-chain triglycerides and polyunsaturated fatty acids have been
proposed as potential contributing factors influencing the efficacy
of enteral nutrition (Goh 2003). Enteral nutritionmay also inhibit
intestinal immune responses by reducing the number of cytokine-
producing cells (Yamamoto 2007).
In a retrospective study, Wilschanski 1996 showed that provid-
ing supplementary enteral nutrition (nocturnal nasogastric sup-
plements), without restriction of normal diet, after successful treat-
ment of active Crohn’s disease by exclusive enteral nutrition, was
associated with prolongation of remission and improved linear
growth in children and adolescents with Crohn’s disease. Verma
2000 have also examined the role of supplementing normal food
with elemental diet in the long term management of adults with
Crohn’s disease. Verma 2000 enrolled 39 consecutive patients in
clinical remission, 21 patients (Group 1) received oral nutritional
supplementation taken in addition to a normal diet whilst 18 pa-
tients (Group 2) were maintained on a normal unrestricted diet.
The patientswere followedup for 12months. A total of 17 patients
(81%) tolerated the nutritional supplementation. On an inten-
tion to treat basis, 10 patients in Group 1 (10/21, 48%) remained
in remission for 12 months, compared to 4/18 (22%) patients in
Group 2 (P < 0.0003). In another study, Verma 2001 also demon-
strated that long term nutritional supplementation allowed the
withdrawal of chronic steroid therapy in patients with steroid-de-
pendent Crohn’s disease. In a controlled cross-over study, Harries
1983 reported a beneficial effect of oral dietary supplementation
(Ensure Plus) in improving nutritional status and decreasing dis-
ease activity in adult patients with Crohn’s disease. Similar find-
ings have been reported by Koga 1993.
The notion that enteral nutritionmay be effective formaintenance
of remission is an attractive proposition. If this is the case, then the
use of steroids and immunosuppressive agents may be minimized
in patients with Crohn’s disease, thereby reducing potentially se-
rious adverse events associated with these medications. Long term
nutritional support and avoidance of steroids may also lead to im-
provements in growth in children and adolescents with Crohn’s
disease. This systematic review was completed over ten years ago
and found just two studies (Akobeng 2007), the results suggested a
potential role for enteral nutrition for the management of patients
with quiescent Crohn’s disease. The aim of this updated systematic
review was to summarise the available evidence concerning the use
of enteral nutrition for the maintenance of remission in Crohn’s
disease.
O B J E C T I V E S
1. To evaluate the efficacy and safety of long term enteral nu-
tritional supplementation for the maintenance of remission in
Crohn’s disease.
2. To examine the impact of formula composition on efficacy.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
Randomised controlled trials were considered for inclusion.
Types of participants
Patients of any age with Crohn’s disease in remission at the time of
study entry were considered for inclusion. Remission should have
been defined by a recognised Crohn’s disease activity index.
Types of interventions
Intervention
Studies that assessed enteral nutrition (polymeric, elemental or
semi-elemental) administered by any route (e.g. oral, nasogastric
or gastrostomy) were considered for inclusion.
Control
Control interventions included no intervention, placebo or other
active interventions for maintenance of remission in quiescent
Crohn’s disease (e.g. a different enteral nutrition formulation or
azathioprine or 6-mercaptopurine).
Types of outcome measures
Primary outcomes
The primary outcome measure was the occurrence of clinical or
endoscopic relapse as defined by the primary studies and expressed
as a percentage of the number of patients randomised.
Secondary outcomes
Secondary endpoints included:
(1) improvements in anthropometric measurements (including
weight and height);
(2) improvements in quality of life;
(3) adverse events;
(4) serious adverse events; and
(5) withdrawal due to adverse events.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases from inception to
5 July 2017 for relevant studies:
1. MEDLINE;
2. Embase;
3. CENTRAL;
4. The Cochrane IBD Group Specialized Trials Register; and|
5. Clinicaltrials.gov.
The search strategies were not limited by language. The search
strategies are reported in Appendix 1.
Searching other resources
The references of all identified studies and relevant systematic
reviews were inspected for more trials. There is some evidence that
data from abstracts can be inconsistent with data in published
articles (Pitkin 1999). Abstract publications were not included in
this review.
Data collection and analysis
Selection of studies
Using the above search strategy, papers that appeared to be poten-
tially relevant were independently identified by two authors (DZ
and JKM). The authors, after reading the full texts, independently
assessed the eligibility of all trials identified based on the inclusion
criteria above. Disagreement among authors was discussed and
agreement reached by consensus.
Data extraction and management
A data extraction formwas developed and used to extract informa-
tion on relevant features and results of included studies. Two au-
thors (DZ and JKM) independently extracted and recorded data
on the predefined checklist. Extracted data included the following
items:
a. characteristics of patients: age, sex, disease distribution, disease
duration, disease activity index;
b. total number of patients originally assigned to each intervention
group;
c. intervention: type and amount of enteral nutrition; mode of
administration;
d. control: no intervention, placebo or other interventions;
e. concurrent medications; and
f. outcomes: time of assessment, length of follow up, type of
Crohn’s disease activity index used, definitions of remission and
relapse, relapse rates, time to relapse, quality of life assessment,
adverse events.
Assessment of risk of bias in included studies
Two authors (DZ and JKM) independently assessed study quality
using theCochrane risk of bias tool (Higgins 2011). The following
domains were assessed: methods used for randomisation and al-
location concealment (selection bias); blinding (performance and
detection bias); incomplete outcome data (attrition bias); selective
reporting of study outcomes; and other potential sources of bias.
Each of the domains was rated as high, low or unclear risk of bias.
An item was assessed as unclear risk of bias if insufficient infor-
mation was available to determine the risk of bias. Any disagree-
ments in the risk of bias assessment were resolved by discussion
and consensus.
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The overall certainty of the evidence was assessed using the
GRADE approach, which allows for overall appraisal of the quality
of evidence so that one can determine confidence in how likely the
effect estimate reflects the true effect (Guyatt 2008; Schunemann
2011). Randomized trials start as high quality of evidence, but can
be downgraded due to risk of bias, indirect evidence, unexplained
heterogeneity, imprecision, and publication bias. After consider-
ation of these factors, the overall certainty of the evidence was
graded as:
- High - further research is unlikely to change confidence in the
estimate of effect;
- Moderate - further research is likely to have an important impact
on confidence in the estimate of effect and may change the effect
estimate;
- Low - further research is very likely to have an important impact
on confidence in the estimate of effect and is likely to change the
effect estimate; or
- Very low - any estimate of effect is very uncertain.
Measures of treatment effect
The Cochrane Collaboration review manager software (RevMan)
was used for the data analyses. Data were analysed according to
the intention-to-treat principle, using as the denominator, the to-
tal number of patients randomised. For dichotomous outcomes
we calculated the risk ratio (RR) and corresponding 95% confi-
dence interval (95% CI). For continuous outcomes, we calculated
the mean difference (MD) and corresponding 95% CI. We used
a random-effects model for the statistical analysis. We explored
heterogeneity using the Chi2 and I2 statistics.
Unit of analysis issues
For studies that reported outcomes at fixed intervals, we planned
to pool data at those time points as well. For a parallel group
design a single measurement for each outcome per participant
was collected. For crossover trials, data from the first part of the
trial (prior to crossover) were extracted. For cluster-randomised
trials, we planned to extract data at the level of the individual.
When more than one efficacy or safety event was reported per
subject, we used the proportion of subjects with at least one event
as the outcome. Separate analyses were planned for different active
comparators.
Dealing with missing data
For missing dichotomous outcomes, we analysed data according
to the intention-to-treat principle. Participants with missing data
were assumed to be treatment failures. For continuous outcomes
we used the number of participants who completed the trial (i.e.
available case analysis). We did not impute any data for missing
continuous outcomes.
Assessment of heterogeneity
For future updates of this systematic review, we plan to explore
heterogeneity using the Chi2 and I2 statistics. We plan to conduct
sensitivity analyses as appropriate to explore potential explanations
for any heterogeneity that is identified.
Assessment of reporting biases
Potential reporting bias was evaluated by comparing outcomes
listed in protocols to publishedmanuscripts. When protocols were
not available, we compared outcomes listed in themethods section
of published manuscripts to those described in the results section.
If a sufficient number of studies are included (i.e. > 10) in the
pooled analyses, we planned to investigate potential publication
bias using funnel plots (Egger 1997).
Data synthesis
We planned to pool data from individual trials when the interven-
tions, patient groups and outcomes were sufficiently similar (as
determined by consensus). We did not pool any studies as none
of the included studies had similar interventions or comparators.
For future updates of this systematic review, we plan to calculate
the pooled RR and 95% CI for dichotomous outcomes and the
pooledMD and corresponding 95%CI for continuous outcomes.
We plan to calculate the standardized mean difference (SMD) and
95% CI when difference scales are used to measure the same out-
come (e.g. different quality of life instruments). We plan to use a
random-effects model for meta-analysis.
Subgroup analysis and investigation of heterogeneity
We did not pre-specify any subgroup analyses.
Sensitivity analysis
We did not pre-specify any sensitivity analyses.
R E S U L T S
Description of studies
The literature search conducted on 27 July 2018 identified 1365
records. Thirteen additional records were identified through other
sources. After duplicates were removed, a total of 933 remained
for review of titles and abstracts. Based on a review of titles and
abstracts, 35 studies were initially identified as being potentially
eligible for inclusion and were selected for full-text review (See
Figure 1). After reviewing the full manuscripts, 27 studies were
excluded for not meeting the inclusion criteria. Seven studies were
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excluded because these studies were not maintenance of remis-
sion studies (Canani 2006; Gorard 1993; Harries 1983; Johnson
2006; Knight 2005; Phylactos 2001; Yamamoto 2005). Fourteen
studies were not randomised controlled trials (Esaki 2005; Giaffer
1991; Hirakawa 1993; Jones 1987; Koga 1993; Matsueda 1995;
Navarro 1982; Nomura 1995; Triantafillidis 2006; Verma 2000;
Wilschanski 1996; Yamamoto 2007; Yamamoto 2010; Yamamoto
2015). Four review articles were excluded (Dray 2005; Forbes
2002; Griffiths 2005; Valentini 2002). One further article was
excluded because separate results were not reported for partici-
pants with Crohn’s disease and ulcerative colitis (Iakovlev 2014).
One randomised study was published in abstract form only and
the full study was never published (Roggero 2003). Four stud-
ies (262 participants) were identified that met the inclusion cri-
teria and these studies were included in the review (Hanai 2012;
Takagi 2006; Triantafillidis 2010; Verma 2001). Four ongoing
studies were also identified (NCT01823042; NCT02201693;
NCT02231814; NCT02843100).
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Figure 1. Figure 1
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Takagi 2006
This study examined the effectiveness of an elemental diet (ED)
as maintenance therapy for Crohn’s disease. Fifty one adults with
Crohn’s disease in remission (defined as a Crohn’s Disease Activity
Index, CDAI < 150) were recruited from two centres in Japan.
Participants were randomised into two groups. The half elemen-
tal diet group (n = 26) received half the amount of their daily
allowance of calories as Elental (Ajinomoto Pharma Co., Tokyo,
Japan) and the remaining half by normal diet. The free diet group
(n = 25) received all their daily calories by normal diet. All partic-
ipants were instructed to take oral mesalazine (2250 to 3000 mg/
day) in accordance with local guidelines. Patients already receiv-
ing azathioprine were allowed to continue taking the medication
throughout the study period. The primary outcome measure was
the clinical relapse rate over a two year period. Relapse was defined
as either a CDAI score of > 200, or the need for therapy to in-
duce remission. In our judgement, there did not appear to be any
clinically relevant differences in baseline characteristics between
the two groups at study entry. Two patients in the half elemental
diet group and four patients in the free diet group were on aza-
thioprine at entry. Six patients withdrew from the half elemental
diet group because they discontinued the supplements, and five
withdrew from the free diet group because they started to take
some supplements during the study period.
Verma 2001
This study investigated the ability of enteral nutrition to maintain
remission and to reduce steroid dependency in Crohn’s disease.
The study which compared an elemental formula (EO28, Scien-
tific Hospital Supplies Ltd, Liverpool, UK) with a polymeric for-
mula (Fortisip, Nutricia, UK) was conducted in the UK. The re-
searchers evaluated 33 adultswithCrohn’s diseasewhowere steroid
dependent and had inactive disease with no bowel symptoms, a
CDAI score of < 150 in the previous 2 weeks and an ESR of < 20
mm/hour. In addition to their normal unrestricted diet, patients
were randomised to receive either E028 (n = 19) or Fortisip (n =
14) orally, to provide 35 to 50% of pre-trial total calorie intake.
Concurrent use of azathioprine, 6-mercaptopurine and 5-aminos-
alicylate preparations was permitted. Participants had disease in
remission for a mean of 22.1 +/- 6.7 months (range 1 to 204) prior
to study entry. Prednisolone was withdrawn gradually at a rate
of 1 mg every 2 weeks until stopped but azathioprine, 6-mercap-
topurine and 5-aminosalicylate were continued at the same doses
throughout the study. Patients were followed up at 1 month, 2
months and then 3 monthly until 12 months or until a relapse oc-
curred. The main outcome measure was ’treatment success’ within
12 months. This was defined as remaining in remission for 12
months (CDAI < 200 and increasing by < 100 from baseline) after
complete withdrawal of steroids. In our judgement, the baseline
characteristics of the two groups were generally similar but the du-
ration of steroid usage before study entry appeared to be longer in
the Fortisip group (61.0 versus 31.6 months in the EO28 group),
and the duration of remission before study entry also appeared to
be longer in the Fortisip group (28.7 versus 11.6 months in the
EO28 group).
Hanai 2012
This study aimed to investigate the use of elemental diet ver-
sus 6-mercaptopurine as maintenance therapy in Crohn’s disease.
Ninety-five eligible patients with a Crohn’s disease activity index
of ≤ 150 were randomly assigned to: 6-mercaptopurine (0.5 to
1.5 mg/kg/day, n = 30), Elental as an elemental diet (≥900 kcal/
day, n = 32), or a no treatment control group (n = 33). Patients
who were taking 5-aminosalicylic acid at entry were allowed to
continue taking the drug at doses of 2250 to 3000 mg per day. Pa-
tients were followed for two years and the rate of relapse (Crohn’s
disease activity index ≥200) was monitored.
Triantafillidis 2010
This study investigated the administration of a special diet (Mod-
ulen IBD) rich in transforming growth factor-β2 compared with
administration of mesalamine, for maintaining remission in pa-
tients with Crohn’s disease. Patients were randomly assigned to
receive either two meals (2 x 50 g) of Modulen IBD plus two reg-
ular meals per day (n = 43) or mesalamine at a dose of 800 mg
three times a day (n = 40) for six months. No other medications
were allowed during the trial period. Patients were assessed at sixth
months after initiation of the trial. The primary outcome was re-
lapse was defined as a CDAI of greater than 150 points or an in-
crease of at least 60 points over baseline. Various anthropometric
parameters and serum estimations including ESR, CRP, platelets,
albumin, vitamin B12 and folic acid were measured at the begin-
ning of the trial and after six months. Of the 83 patients initially
included in the study, 76 (36 in the Modulen group and 30 in the
mesalamine group) completed the trial.
Risk of bias in included studies
The results of the risk of bias analysis are summarized in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
One study had a low risk of bias for random sequence generation
and allocation concealment (Takagi 2006). The remaining three
studies were rated to have an unclear risk of bias due to insufficient
information to permit judgement for both of these items (Hanai
2012; Triantafillidis 2010; Verma 2001).
Blinding
One study had a high risk of bias for blinding of participants but
low risk of bias for blinding of outcome assessment (Takagi 2006).
The remaining three studies were rated as unclear risk of bias due
to insufficient information to permit judgment for both of these
items (Hanai 2012; Triantafillidis 2010; Verma 2001).
Incomplete outcome data
Three studies were rated as low risk of bias for incomplete outcome
data (Hanai 2012; Takagi 2006; Verma2001), while one studywas
rated as high risk of bias for incomplete outcome data reporting
(Triantafillidis 2010).
Selective reporting
All studies were rated to have low risk of bias in terms of selective
reporting bias.
Other potential sources of bias
All studies appeared to be free from other sources of bias and were
rated to be low risk of bias for this item.
Effects of interventions
See: Summary of findings for the main comparison
Elemental formula supplements compared to polymeric formula
supplements for maintenance of remission in Crohn’s disease;
Summary of findings 2 Elemental formula supplements
compared to no supplementation for maintenance of remission
in Crohn’s disease; Summary of findings 3 Enteral nutrition
compared to 6-MP for maintenance of remission in Crohn’s
disease; Summary of findings 4 Enteral nutrition compared to
mesalamine for maintenance of remission in Crohn’s disease
A meta-analyses was originally planned for this review. However,
on closer examination of the results of the included primary stud-
ies, it became obvious that pooled statistical analyses were not pos-
sible. This is because the control interventions, and the way out-
comes were assessed differed greatly across the four studies. The
results of the individual studies are therefore presented below.
Elemental diet versus non-elemental (polymeric) diet
The effect of an elemental diet compared to a polymeric diet on
remission rates or withdrawal due to adverse events is uncertain.
After 12 months, 58% (11/19) of participants in the elemental
diet group relapsed compared to 57% (8/14) of participants in the
polymeric diet group (RR 1.01, 95% CI 0.56 to 1.84; GRADE
very low certainty evidence). Thirty-two per cent (6/19) of par-
ticipants in the elemental diet group were intolerant to the en-
teral nutritional formula because of taste or smell and were with-
drawn from the study in the first 2 weeks compared to zero partic-
ipants (0/14) in the polymeric diet group (RR 9.75, 95% CI 0.59
to 159.93; GRADE very low certainty evidence). Verma 2001
reported that three patients (9%) developed steroid withdrawal
symptoms, including muscle aches, depression, feeling generally
unwell and mild abdominal pain. The authors did not report
which group these patients belonged to. No serious adverse events
were reported. Verma 2001 did not report on changes in weight
or height in a manner that would allow for a comparison between
elemental and polymeric formulas. Verma 2001 did not report on
quality of life.
Elemental diet versus free diet (no supplementation)
The effect of an elemental diet compared to a normal free diet on
relapse rates is uncertain. After a mean follow up of 11.9 months,
35% (9/26) of participants in the elemental diet group relapsed
compared to 64% (16/25) of participants in the free diet group
(RR 0.54, 95% CI 0.30 to 0.99, P = 0.05; GRADE very low
certainty evidence). No adverse events or serious adverse events
were reported (Takagi 2006). Takagi 2006 reported that there were
no significant differences in weight change between the elemental
diet and free diet groups throughout the study. Takagi 2006 did
not report on changes in height or quality of life.
Elemental diet versus 6-mercaptopurine
The effect of an elemental diet compared to 6-MP on relapse rates
or adverse events is uncertain. Thirty-eight per cent (12/32) of
participants in the elemental diet group relapsed at 12 months
compared to 23% (7/30) of participants in the 6-mercaptopurine
group (RR 1.61; 95%CI 0.73 to 3.53; GRADE very low certainty
evidence). Three per cent (1/32) of participants in the elemen-
tal diet group had an adverse event compared to 13% (4/30) of
participants in the 6-mercaptopurine group (RR 0.23, 95% CI
0.03 to 1.98;GRADE very low certainty evidence). Adverse events
in the elemental diet group included surgery due to worsening
Crohn’s disease (one participant). Adverse events in the 6-mercap-
topurine group included liver injury (two participants), hair loss
(one participant) surgery due to an abscess (one participant). No
withdrawals due to adverse events or serious adverse events were
reported (Hanai 2012). Hanai 2012 did not report on changes in
weight, height or quality of life.
Non-elemental (polymeric) diet versus mesalamine
The effect of a polymeric diet compared to mesalamine on relapse
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rates and weight is uncertain. Forty-two per cent (18/43) of par-
ticipants in the polymeric diet group relapsed at six months com-
pared to 55% (22/40) of participants in the mesalamine group
(RR 0.76; 95% CI 0.49 to 1.19; GRADE low certainty evidence).
Triantafillidis 2010 reported that two patients experienced nausea
and four haddiarrhoea. These adverse eventswere attributed tonu-
tritional treatment. It is unclear if any patients in the mesalamine
group had an adverse event. No withdrawals due to adverse events
or serious adverse events were reported. Although participants in
the polymeric group gained more weight over the six month study
period than participants in the mesalamine group, this difference
does not appear to be clinically meaningful (MD 1.90, 95% CI -
4.62 to 8.42;GRADEmoderate certainty evidence). Triantafillidis
2010 did not report on changes in height or quality of life.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Elemental formula supplements compared to no supplementation for maintenance of remission in Crohn’s disease
Patient or population: Part icipants with Crohn’s disease in remission
Setting: Outpat ient
Intervention: Elemental formula supplements
Comparison: No supplementat ion
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with no supple-
mentation
Risk with elemental
formula supplements
Relapse
Follow-up: 12 months
640 per 1,000 346 per 1,000
(192 to 634)
RR 0.54
(0.30 to 0.99)
51
(1 RCT)
⊕©©©
VERY LOW 12
Change in weight (kg)
Follow-up: 12 months
See comments This study reported no
dif ferences in weight
change between the
two diet groups (mean
weights and standard
deviat ions were not re-
ported)
Change in height Not reported This outcome was not
reported
Change in quality of life Not reported This outcome was not
reported
Adverse events
Follow-up: 12 months
0 per 1,000 0 per 1,000
(0 to 0)
not est imable 51
(1 RCT)
- No adverse events were
reported
Serious adverse events
Follow-up: 12 months
0 per 1,000 0 per 1,000
(0 to 0)
not est imable 51
(1 RCT)
- No adverse events were
reported
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Withdrawal due to ad-
verse events
Follow-up: 12 months
0 per 1,000 0 per 1,000
(0 to 0)
not est imable 51
(1 RCT)
- No adverse events were
reported
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to high risk of bias for blinding of part icipants and personnel
2 Downgraded two levels due to very serious imprecision (25 events)
1
6
E
n
te
ra
l
n
u
tritio
n
fo
r
m
a
in
te
n
a
n
c
e
o
f
re
m
issio
n
in
C
ro
h
n
’s
d
ise
a
se
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Enteral nutrition compared to 6-MP for maintenance of remission in Crohn’s disease
Patient or population: Part icipants with Crohn’s disease in remission
Setting: Outpat ient
Intervention: Enteral nutrit ion
Comparison: 6-MP
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with 6-MP Risk with enteral nutri-
tion
Relapse
Follow-up: 24 months
233 per 1,000 376 per 1,000
(170 to 824)
RR 1.61
(0.73 to 3.53)
62
(1 RCT)
⊕©©©
VERY LOW 12
Change in weight Not reported This outcome was not
reported
Change in height Not reported This outcome was not
reported
Change in quality of life Not reported This outcome was not
reported
Adverse events
Follow-up: 24 months
133 per 1,000 31 per 1,000
(4 to 264)
RR 0.23
(0.03 to 1.98)
62
(1 RCT)
⊕⊕©©
LOW 3
Serious adverse events
Follow-up: 24 months
0 per 1,000 0 per 1,000
(0 to 0)
not est imable 62
(1 RCT)
- The authors reported
that no serious adverse
events were observed
Withdrawal due to ad-
verse events
Not reported This outcome was not
reported
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to unclear risk of bias for random sequence generat ion, allocat ion concealment, blinding of
part icipants and personnel and blinding of outcome assessment
2 Downgraded two levels due to very serious imprecision (19 events)
3 Downgraded two levels due to very serious imprecision (5 events)
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Enteral nutrition compared to mesalamine for maintenance of remission in Crohn’s disease
Patient or population: Part icipants with Crohn’s disease in remission
Setting: Outpat ient
Intervention: Enteral nutrit ion
Comparison: Mesalamine
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with mesalamine Risk with enteral nutri-
tion
Relapse
Follow-up: 6 months
550 per 1,000 418 per 1,000
(270 to 655)
RR 0.76
(0.49 to 1.19)
83
(1 RCT)
⊕⊕©©
LOW 12
40 events
Change in weight (kg)
Follow-up: 6 months
The mean weight was 0 MD 1.9 higher
(4.62 lower to 8.42
higher)
- 66
(1 RCT)
⊕⊕©©
LOW 34
Weight measurements
were available for 66
part icipants
Weight
was 1.9 kg lower in the
mesalamine group
Change in height Not reported This outcome was not
reported
Change in quality of life Not reported This outcome was not
reported
Adverse events
Follow-up: 6 months
Not reported Two patients in the en-
teral nutrit ion group ex-
perienced nausea and
four had diarrhoea
It is unclear if any
part icipants in the
mesalamine group had
an adverse event19
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Serious adverse events Not reported This outcome was not
reported
Withdrawal due to ad-
verse events
Not reported This outcome was not
reported
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to unclear risk of bias for random sequence generat ion, allocat ion concealment, blinding of
part icipants and personnel and blinding of outcome assessment
2 Downgraded one level due to serious imprecision (40 events)
3 Downgraded one level due to serious imprecision (66 part icipants)
4 Downgraded one level due to high risk of attrit ion bias
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D I S C U S S I O N
This updated systematic review includes four studies (262 adult
participants). The trials were wide ranging and have significant
clinical and methodological heterogeneity. The sample sizes of the
included studies were generally small and the studies may have
lacked statistical power. It is therefore difficult to draw any definite
conclusions from these data. Very low certainty evidence suggests
that a supplementary elemental diet may be superior to a free diet
for maintenance of remission in Crohn’s disease. Participants who
received half of their total daily calorie requirements as elemental
diet and the remaining half by normal diet had a lower chance
of relapse at 12 months compared to participants who received a
free diet (Takagi 2006). No adverse effects were reported in this
study. More research is required to confirm this benefit. Very low
certainty evidence suggests no difference in efficacy between el-
emental and polymeric formulas. The Verma 2001 study found
no difference between an elemental and a polymeric formula with
regard to the promotion of steroid withdrawal, and prevention of
the need for surgery or steroid therapy. However, thirty-two per
cent (6/19) of participants in the elemental diet group were not
able to tolerate the enteral nutritional formula because of taste or
smell and were withdrawn from the study. Tolerance issues were
not reported with the polymeric formula. Dropouts in enteral nu-
trition trials are frequently due to poor acceptance of a nasogastric
tube and unpalatable formulations. The development of palatable
enteral nutrition formulations that can be delivered without use
of a nasogastric tube may lead to increased patient adherence with
this therapy. A claim of equal efficacy for elemental and polymeric
formulas would require evidence from a formal equivalence trial.
More research including adequately powered trials is required to
determine the optimal enteral nutrition formulation for use in
people with quiescent Crohn’s disease.
Very low certainty evidence suggests no difference in efficacy be-
tween an elemental diet and 6-mercaptopurine. The Hanai 2012
study compared elemental diet with 6-mercaptopurine and found
no difference in relapse or adverse event rates. The only adverse
event reported in the elemental diet group was surgery due to
worsening Crohn’s disease. Adverse events in the 6-mercaptop-
urine group included liver injury in two participants, hair loss in
one participant and surgery to treat an abscess in one participant.
No serious adverse events were reported in this study. More re-
search is needed to allow for a firm conclusion regarding the rela-
tive efficacy and safety of enteral nutrition and 6-mercaptopurine
for maintenance therapy in Crohn’s disease.
Low certainty evidence suggests no difference in efficacy between
a polymeric diet and mesalamine. Triantafillidis 2010 compared a
polymeric diet to mesalamine and found no difference in relapse
rates at six months, although the trend was towards superiority of
elemental diet. Two participants the polymeric diet group experi-
enced nausea and four had diarrhoea. It is unclear if any partici-
pants in the mesalamine group had any adverse events. No serious
side effects were reported in this study. More research is needed to
allow for a firm conclusion regarding the relative efficacy and sa-
fety of enteral nutrition and mesalamine for maintenance therapy
in Crohn’s disease.
Long term nutritional support and avoidance of steroids may
also lead to improvements in growth in children and adolescents
with Crohn’s disease (Yamamoto 2007; Verma 2000; Wilschanski
1996). However, none of the included studies assessed the use
of enteral nutrition in children with quiescent Crohn’s disease.
Enteral nutrition may provide a benefit for children with active
Crohn’s disease (Narula 2018). The use of enteral nutrition in
children with quiescent Crohn’s diseases should be investigated.
When considering the results of this systematic review in the con-
text of the previously published review (Akobeng 2007), it is dis-
appointing that the size and scope of the evidence base has not
increased more. Indeed, whilst a randomised controlled trial is al-
ways a significant undertaking, such trials that focus on dietary
interventions are in many ways a less daunting and costly proposal
than drug interventions and it would have been expected that
this, combined with the promising results reported in the previous
publication, would have led to many more studies. Future studies
should be well-powered and should also investigate the amount of
enteral nutritional supplements that will produce optimal benefits.
These studies should also assess cost-effectiveness and the impact
of supplementation on patients’ quality of life.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results for the outcomes assessed in this review are uncertain
and no firm conclusions regarding the efficacy and safety of enteral
nutrition in quiescent CD can be drawn.
Implications for research
More research is needed to determine the efficacy and safety of
using enteral nutrition as maintenance therapy in Crohn’s disease.
Larger well-powered randomised controlled trials are needed. Fu-
ture studies should compare enteral nutrition with interventions
such as methotrexate, azathioprine, infliximab and other active
drugs that are known to be effective for maintaining remission in
Crohn’s disease. Large numbers of patients would need to be ran-
domised for these studies. Future studies should also investigate
the amount of enteral nutritional supplements that will produce
optimal benefits. These studies should also assess cost-effective-
ness and the impact of supplementation on patients’ quality of life.
Currently, there are four ongoing studies (estimated enrolment of
280 participants). This review will be updated when the results of
these studies are available.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Hanai 2012
Methods Randomised controlled trial
Participants 95 patients, between the ages of 19 to 48, with a diagnosis of Crohn’s disease and in
clinical remission as defined by CDAI < 150
Interventions 30 patients received 6-mercaptopurine, 32 patients received enteral nutrition (elemental
diet), 33 patients served as the control group and did not receive any additional medi-
cations
Outcomes Primary outcome was rate of relapse over the 2 years follow-up time, relapse was defined
asCDAI > 200 or the need for an additionalmedication to suppress worsening symptoms
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described
Allocation concealment (selection bias) Unclear risk Allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No patients were lost to follow-up
Selective reporting (reporting bias) Low risk Prespecified outcomes reported
Other bias Low risk The study appears to be free from other sources of bias
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Takagi 2006
Methods Randomised controlled trial
Participants 51 adults (37 men) with Crohn’s disease in remission
Interventions 26 received half of their daily allowance as elemental diet and half as normal diet. 25
received all their daily allowance as normal diet
Outcomes Primary outcome: relapse within 2 years. Relapse was defined as a CDAI score of > 200
or the need for therapy to induce remission
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation generated by an independent randomi-
sation centre
Allocation concealment (selection bias) Low risk Allocation was performed by an independent randomi-
sation centre
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants in the ED group took their ED as powder in
solution; participants in the free diet group took all their
nutrients via their usual unrestricted meals
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “To maintain the blinding of the principal investigators
at each site, the results of the lab tests and the CDAI were
reviewed by co-investigators who had no contact with
the patients, and these results were reported in a separate
case report form”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No patients were lost to follow-up
Selective reporting (reporting bias) Low risk Prespecified outcomes were reported
Other bias Low risk The study appears to be free from other sources of bias
Triantafillidis 2010
Methods Randomised controlled trial
Participants Eighty-three patients with Crohn’s disease in remission, defined as CDAI < 150
Interventions 36 patients received enteral nutrition (a non-elemental polymeric diet - Modulen) and
30 patients received mesalamine
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Triantafillidis 2010 (Continued)
Outcomes Relapse was defined as CDAI > 150 or at least 60 points over baseline
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not described
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Patients lost to follow-up not described
Selective reporting (reporting bias) Low risk Prespecified outcomes were reported
Other bias Low risk The study appears to be free of other sources of bias
Verma 2001
Methods Randomised controlled trial
Participants 33 adults (11 men) with Crohn’s disease in remission
Interventions 19 participants received 35-50% of their pretrial calorie intake as elemental diet (EO28
Extra, Scientific Hospital Supplies Ltd, Liverpool, UK)
14 participants received 35-50%of their pretrial calorie intake as polymeric diet (Fortisip,
Nutricia, UK)
Outcomes Primary outcome: Treatment success within 12 months
This was defined as remaining in remission for 12 months (CDAI < 200 and increasing
by < 100 from baseline) after complete withdrawal of steroids
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Verma 2001 (Continued)
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not described
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No patients were lost to follow-up
Selective reporting (reporting bias) Low risk Prespecified outcomes were reported
Other bias Low risk The study appears to be free from other sources of bias
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Canani 2006 Not a maintenance study
Dray 2005 Review article
Esaki 2005 Not an RCT
Forbes 2002 Review article
Giaffer 1991 Not an RCT
Gorard 1993 Not a maintenance study
Griffiths 2005 Review article
Harries 1983 Not a maintenance study
Hirakawa 1993 Not an RCT
Iakovlev 2014 Does not report separate results for Crohn’s disease and ulcerative colitis; does not report number of patients
randomised to each group
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(Continued)
Johnson 2006 Not a maintenance study
Jones 1987 Not an RCT; studied food exclusion diets, not enteral nutrition
Knight 2005 Not a maintenance study
Koga 1993 Not an RCT
Matsueda 1995 Not an RCT
Navarro 1982 Not an RCT
Nomura 1995 Not an RCT
Phylactos 2001 Not a maintenance study
Roggero 2003 Abstract publication of RCT
Never published in full
Triantafillidis 2006 Not an RCT
Valentini 2002 Review article
Verma 2000 Not an RCT
Wilschanski 1996 Not an RCT
Yamamoto 2005 Not a maintenance study
Yamamoto 2007 Not an RCT
Yamamoto 2010 Not an RCT
Yamamoto 2015 Not an RCT
Characteristics of ongoing studies [ordered by study ID]
NCT01823042
Trial name or title A Randomized, Controlled, Open-label Study to Assess the Efficacy of Enteral Nutrition in Fill of the
Treatment Blank Period of the Postoperative Maintain Remission Medication for Crohn’s Disease (CD)
Methods Randomized, controlled, open-label study
Participants All patients, aged 18 to 75, with an established diagnosis of Crohn’s disease with a CDAI score < 150 at week
0
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NCT01823042 (Continued)
Interventions One group received azathioprine, one group received azathioprine and enteral nutrition
Outcomes Change in CDAI at week 0, week 4, week 8 and week 12
Starting date October 2012
Contact information Zhu Weiming, PhD, MD, dr zhuweiming@126.com
Notes Estimated enrolment: 100
NCT02201693
Trial name or title Randomised Trial Comparing 12 Months of Cyclic Enteral Nutrition to Supplementary Enteral Nutrition
as Maintenance Therapy for Pediatric Crohn’s Disease
Methods Randomised trial
Participants Patients, aged 6 to 18, with confirmed Crohn’s disease, who have completed a cycle of induction therapy for
at least 6 weeks
Interventions One group received cyclic exclusive enteral nutrition (100% of daily calories) for two weeks every 8 weeks;
one group received supplementary enteral nutrition (25% daily calories)
Outcomes The first relapse at 12 months assessed with PCDAI, clinical remission assessed with PCDAI, CDAI and
PGA
Starting date December 2014
Contact information Frank Ruemmele, MD, PhD, frank.ruemmele@nck.aphp.fr
Notes Estimated enrolment: 100
NCT02231814
Trial name or title Dietary Therapy Using Partial Enteral Nutrition and the Crohn’s Disease Exclusion Diet (CDED) for Induc-
tion and Maintenance of Remission in Mild to Moderate Crohn’s Disease in Adults- A Pilot Study
Methods Prospective, open-label, randomised controlled pilot trial
Participants Patients, aged 18 to 55, with an established Crohn’s disease, with HBI between 5 and 15
Interventions One group will receive the Crohn’s disease exclusion diet and partial enteral nutrition, while another group
receives the Crohn’s disease exclusion diet alone. The maintenance phase will be assessed from weeks 13
through 24
Outcomes Steroid free mission assessed at week 6, 12 and 24
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NCT02231814 (Continued)
Starting date December 2016
Contact information Arie Levine, MD, alevine@wolfson.health.gov.il
Notes Estimated enrolment: 40
NCT02843100
Trial name or title ModifiedExclusive EnteralNutritionWith theCrohn’sDisease ExclusionDiet for Induction andMaintenance
of Remission and Re-biosis
Methods Randomized, controlled, pilot trial
Participants Patients aged 8 to 18 with mild to severe Cron’s disease, with PCDAI between 15 and 47.5
Interventions One group will receive exclusive enteral nutrition for two weeks followed by twelve weeks of partial enteral
nutrition and Crohn’s disease exclusion diet; one group will receive standard exclusive enteral nutrition for
eight weeks, followed by gradual reduction of enteral nutrition by week 12
Outcomes Steroid free remission defined as PCDAI < 10 at week 24, biologic therapy free remission defined as PCDAI
< 10 at week 24
Starting date January 2017
Contact information Arie Levine, MD, alevine@wolfson.health.gov.il
Notes Estimated enrolment: 40
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D A T A A N D A N A L Y S E S
Comparison 1. Elemental diet versus non-elemental (polymeric) diet
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Relapse at 12 months 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Withdrawals due to adverse
events
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 2. Elemental diet versus free diet (no supplementation)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Relapse at 12 months 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Adverse events 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Serious adverse events 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Withdrawals due to adverse
events
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 3. Elemental diet versus 6-mercaptopurine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Relapse at 24 months 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Adverse events 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Serious adverse events 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Withdrawals due to adverse
events
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Comparison 4. Non-elemental (polymeric) diet versus mesalamine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Relapse at 6 months 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Weight 1 Mean Difference (IV, Random, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Elemental diet versus non-elemental (polymeric) diet, Outcome 1 Relapse at
12 months.
Review: Enteral nutrition for maintenance of remission in Crohn’s disease
Comparison: 1 Elemental diet versus non-elemental (polymeric) diet
Outcome: 1 Relapse at 12 months
Study or subgroup Elemental diet Polymeric diet Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Verma 2001 11/19 8/14 1.01 [ 0.56, 1.84 ]
0.01 0.1 1 10 100
Favours elemental Favours polymeric
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Analysis 1.2. Comparison 1 Elemental diet versus non-elemental (polymeric) diet, Outcome 2 Withdrawals
due to adverse events.
Review: Enteral nutrition for maintenance of remission in Crohn’s disease
Comparison: 1 Elemental diet versus non-elemental (polymeric) diet
Outcome: 2 Withdrawals due to adverse events
Study or subgroup Elemental diet Polymeric diet Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Verma 2001 6/19 0/14 9.75 [ 0.59, 159.93 ]
0.01 0.1 1 10 100
Favours elemental Favours polymeric
Analysis 2.1. Comparison 2 Elemental diet versus free diet (no supplementation), Outcome 1 Relapse at 12
months.
Review: Enteral nutrition for maintenance of remission in Crohn’s disease
Comparison: 2 Elemental diet versus free diet (no supplementation)
Outcome: 1 Relapse at 12 months
Study or subgroup Elemental diet No supplements Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Takagi 2006 9/26 16/25 0.54 [ 0.30, 0.99 ]
0.01 0.1 1 10 100
Favours elemental Favours no supplements
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Analysis 2.2. Comparison 2 Elemental diet versus free diet (no supplementation), Outcome 2 Adverse
events.
Review: Enteral nutrition for maintenance of remission in Crohn’s disease
Comparison: 2 Elemental diet versus free diet (no supplementation)
Outcome: 2 Adverse events
Study or subgroup Elemental diet No supplements Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Takagi 2006 0/26 0/25 Not estimable
0.01 0.1 1 10 100
Favours elemental Favours no supplements
Analysis 2.3. Comparison 2 Elemental diet versus free diet (no supplementation), Outcome 3 Serious
adverse events.
Review: Enteral nutrition for maintenance of remission in Crohn’s disease
Comparison: 2 Elemental diet versus free diet (no supplementation)
Outcome: 3 Serious adverse events
Study or subgroup Elemental diet No supplements Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Takagi 2006 0/26 0/25 Not estimable
0.01 0.1 1 10 100
Favours elemental Favours no supplements
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Analysis 2.4. Comparison 2 Elemental diet versus free diet (no supplementation), Outcome 4 Withdrawals
due to adverse events.
Review: Enteral nutrition for maintenance of remission in Crohn’s disease
Comparison: 2 Elemental diet versus free diet (no supplementation)
Outcome: 4 Withdrawals due to adverse events
Study or subgroup Elemental diet No supplements Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Takagi 2006 0/26 0/25 Not estimable
0.01 0.1 1 10 100
Favours elemental Favours no supplements
Analysis 3.1. Comparison 3 Elemental diet versus 6-mercaptopurine, Outcome 1 Relapse at 24 months.
Review: Enteral nutrition for maintenance of remission in Crohn’s disease
Comparison: 3 Elemental diet versus 6-mercaptopurine
Outcome: 1 Relapse at 24 months
Study or subgroup Elemental diet 6-MP Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hanai 2012 12/32 7/30 1.61 [ 0.73, 3.53 ]
0.01 0.1 1 10 100
Favours elemental Favours 6-MP
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Analysis 3.2. Comparison 3 Elemental diet versus 6-mercaptopurine, Outcome 2 Adverse events.
Review: Enteral nutrition for maintenance of remission in Crohn’s disease
Comparison: 3 Elemental diet versus 6-mercaptopurine
Outcome: 2 Adverse events
Study or subgroup Elemental diet 6-MP Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hanai 2012 1/32 4/30 0.23 [ 0.03, 1.98 ]
0.01 0.1 1 10 100
Favours elemental Favours 6-MP
Analysis 3.3. Comparison 3 Elemental diet versus 6-mercaptopurine, Outcome 3 Serious adverse events.
Review: Enteral nutrition for maintenance of remission in Crohn’s disease
Comparison: 3 Elemental diet versus 6-mercaptopurine
Outcome: 3 Serious adverse events
Study or subgroup Elemental diet 6-MP Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hanai 2012 0/32 0/30 Not estimable
0.01 0.1 1 10 100
Favours elemental Favours 6-MP
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Analysis 3.4. Comparison 3 Elemental diet versus 6-mercaptopurine, Outcome 4 Withdrawals due to
adverse events.
Review: Enteral nutrition for maintenance of remission in Crohn’s disease
Comparison: 3 Elemental diet versus 6-mercaptopurine
Outcome: 4 Withdrawals due to adverse events
Study or subgroup Elemental diet 6-MP Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hanai 2012 0/32 0/30 Not estimable
0.01 0.1 1 10 100
Favours elemental Favours 6-MP
Analysis 4.1. Comparison 4 Non-elemental (polymeric) diet versus mesalamine, Outcome 1 Relapse at 6
months.
Review: Enteral nutrition for maintenance of remission in Crohn’s disease
Comparison: 4 Non-elemental (polymeric) diet versus mesalamine
Outcome: 1 Relapse at 6 months
Study or subgroup Polymeric diet Mesalamine Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Triantafillidis 2010 18/43 22/40 0.76 [ 0.49, 1.19 ]
0.01 0.1 1 10 100
Favours polymeric Favours mesalamine
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Analysis 4.2. Comparison 4 Non-elemental (polymeric) diet versus mesalamine, Outcome 2 Weight.
Review: Enteral nutrition for maintenance of remission in Crohn’s disease
Comparison: 4 Non-elemental (polymeric) diet versus mesalamine
Outcome: 2 Weight
Study or subgroup Polymeric diet Mesalamine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Triantafillidis 2010 36 65.1 (13.3) 30 63.2 (13.6) 1.90 [ -4.62, 8.42 ]
-100 -50 0 50 100
Favours mesalamine Favours polymeric
A P P E N D I C E S
Appendix 1. Search strategies
MEDLINE on OVID:
1. random$.tw.
2. factorial$.tw.
3. (crossover$ or cross over$ or cross-over$).tw.
4. placebo$.tw.
5. single blind.mp.
6. double blind.mp.
7. triple blind.mp.
8. (singl$ adj blind$).tw.
9. (double$ adj blind$).tw.
10. (tripl$ adj blind$).tw.
11. assign$.tw.
12. allocat$.tw.
13. randomized controlled trial/
14. or/1-13
15. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
16. 14 not 15
17. crohn*.mp.
18. exp Crohn disease/
19. ileitis.mp.
20. enteritis, regional.mp.
21. or/17-20
22. 16 and 21
23. enteral nutrition.mp. or exp enteral nutrition/
24. food.mp. or exp food/
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25. diet.mp. or exp diet/
26. polymeric diet.mp. or exp polymeric diet/
27. elemental diet.mp. or exp elemental diet/
28. or/23-27
29. 22 and 28
Embase on OVID:
1. random$.tw.
2. factorial$.tw.
3. (crossover$ or cross over$ or cross-over$).tw.
4. placebo$.tw.
5. single blind.mp.
6. double blind.mp.
7. triple blind.mp.
8. (singl$ adj blind$).tw.
9. (double$ adj blind$).tw.
10. (tripl$ adj blind$).tw.
11. assign$.tw.
12. allocat$.tw.
13. crossover procedure/
14. double blind procedure/
15. single blind procedure/
16. triple blind procedure/
17. randomized controlled trial/
18. or/1-17
19. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
20. 18 not 19
21. crohn*.mp.
22. exp Crohn disease/
23. ileitis.mp.
24. enteritis, regional.mp.
25. or/21-24
26. 20 and 25
27. enteral nutrition.mp. or exp enteral nutrition/
28. food.mp. or exp food/
29. diet.mp. or exp diet/
30. polymeric diet.mp. or exp polymeric diet/
31. elemental diet.mp. or exp elemental diet/
32. or/27-31
33. 26 and 32
CENTRAL
#1. crohn*
#2. enteral nutrition or food or diet or polymeric diet or elemental diet
#3. #1 and #2
Cochrane IBD Group Specialized Trials Register
1. Crohn
2. Enteral nutrition
3. 1 and 2
Clinicaltrials.gov
1. Crohn
2. Enteral nutrition
3. 1 and 2
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WH A T ’ S N E W
Last assessed as up-to-date: 27 July 2018.
Date Event Description
27 July 2018 New search has been performed New literature search was run on 27 July 2018. Two new
studies were added to the review
27 July 2018 New citation required and conclusions have changed Updated review with changes to the conclusions and new
authors
D E C L A R A T I O N S O F I N T E R E S T
Anthony K Akobeng: None known
Dongni Zhang: None known
Morris Gordon has received travel fees to attend international scientific and training meeting such as DDW, Advances in IBD,
ESPGHAN, BSPGHAN and Cochrane focused international events from companies including: Abbott, Nutricia, Biogaia, Ferring,
Allergan, Tillotts. None of these companies have had any involvement in any works completed byme and I have never had any payments
for any other activates from these companies.
John K MacDonald: None known
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This review update includes a PRISMA flow diagram, a risk of bias assessment of included studies (to replace the Jadad scale), a GRADE
analysis and Summary of Findings tables, a per-protocol analysis for the Triantafillidis 2010 study (drop-outs were not described) and
the inclusion of adverse event outcomes. For the original published version of this review, we contacted leaders in the field and drug
companies to identify other potentially eligible studies (Akobeng 2007). This did not identify any studies and we did not do this for
the updated version of this review.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Enteral Nutrition; Crohn Disease [prevention & control; ∗therapy]; Randomized Controlled Trials as Topic; Secondary Prevention
MeSH check words
Humans
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